published meta-analysis   sensitivity analysis   studies

anticoagulation, intermediate prophylactic dose in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsINSPIRATION, 2021 1.09 [0.78; 1.53] 1.09[0.78; 1.53]INSPIRATION, 202110%562NAnot evaluable Major bleedingdetailed resultsINSPIRATION, 2021 1.83 [0.53; 6.34] 1.83[0.53; 6.34]INSPIRATION, 202110%562NAnot evaluable Thromboembolic eventsdetailed resultsINSPIRATION, 2021 1.07 [0.76; 1.49] 1.07[0.76; 1.49]INSPIRATION, 202110%562NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-03-29 02:40 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 901 - roots T: 290